Recent News

• 02.18.2025 - Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
• 02.18.2025 - Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
• 01.21.2025 - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
• 01.21.2025 - Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
• 12.12.2024 - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
• 12.12.2024 - Kiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
• 12.03.2024 - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
• 12.03.2024 - Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
• 10.23.2024 - Cell Therapy Specialist Lead
• 10.23.2024 - Cell Therapy Specialist I/II

Recent Filings

• 02.14.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.03.2025 - 8-K/A Current report
• 02.03.2025 - 8-K Current report
• 01.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.11.2024 - 8-K Current report
• 11.08.2024 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2024 - 8-K Current report